A. Cell line name and tissue derived from Method of analysis Frequency and subcellular localisation of PASD1 expression Reference FEDP (ALK-negative anaplastic large-cell lymphoma) Immunostaining PASD1-1, but not PASD1-2, positive [44] G361 (melanoma) Tissue arrays PASD1 positive [35] Granta519 (mantle cell lymphoma cell line) Immunostaining Nuclear staining with PASD1-1 and PASD1-2 antibodies, while strong cytoplasmic labelling with PASD1-2 was also observed in a subpopulation of Granta519 cells. [44] H1299 (lung cancer) RQ-PCR Immunostaining PASD1 positive >99% expression of PASD1-2 [15] [63] Hn5 (head and neck cancer) RQ-PCR PASD1 positive [15] Jurkats (T cell leukaemia) RQ-PCR PASD1 positive [15] K562 (CML) Immunostaining 17.6 ± 3.6% nuclear staining [63] KH-M2 established from the pleural effusion of a patient with Hodgkin's disease of mixed cellular type Immunostaining Nuclear staining with PASD1-1 and PASD1-2 antibodies [44] KMS-12-BM MM cell line Immunostaining Expression of PASD1-1 and PASD 1-2. Expression in >95% nuclei of cells [48] MOLP-8 MM cell line OCI-LY3 (non-germinal centre diffuse large B-cell lymphoma) Immunostaining PASD 1-1 strongly labelled the cell membrane and cytoplasm while there was no staining of these cells with PASD1-2 [44] Thiel (MM) Immunostaining Nuclear staining PASD 1-1 and PASD1-2 staining 5 of 11 multiple myeloma cell lines, of which THIEL and RPMI8226 expressed both PASD1 mRNA and protein. [49] [44] RPMI8226 (MM) SW480 (colon cancer) Tissue arrays RQ-PCR Immunostaining and flow cytometry PASD1 positive Expression of PASD1-2 [15,35,63]

B. Tissue Technique Reference Expression in 25 of 68 solid tumours Probing Northern blot arrays [35]   A range of normal tissues including brain, liver, kidney, placenta, breast, uterus or ovary RT-PCR and ICC [15,44] 4 of 12 AML patients, and 1 of 6 CML patients  RT-PCR and RQ-PCR [15] Normal testicular tissues expression was only found in the nuclei of a subpopulation of spermatogonia. Labelling intensity decreased with maturity of the spermatogoa. Immunostaining [44] Examples of PASD1-1: 21 of 51 DLBCL, 4 of 9 mantle cell lymphoma, 4 of 15 follicular lymphomas, 4 of 12 Burkitt’s lymphoma. PASD1-2: 11 of 52 DLBCL, 2 of 4 MM, 4/10 peripheral T cell lymphoma and a range of other tumour cells from patients with haematological malignancies. 41% overall. PASD1-1 was mostly cytoplasmic and weak nuclear staining in DLBCL and MM. Stronger labelling towards the periphery of the tumour.PASD1-2 was nuclear staining. Immunostaining [44] 14 of 16 primary MM samples including 9 presentation and 7 previously treated cases RQ-PCR [49] Two of four primary MM tumour samples  ICC [49] PASD1 (22/25) cell lines derived from 21 B- and 4 T-cell malignancies RT-PCR [50] 3.4% of 320 newly diagnosed and 264 relapse cases of MM Microarray using Affymetrix GeneChips [51] Not found in 78 basal cell carcinoma RQ-PCR [53] AML: Acute Myeloid Leukaemia; CML: Chronic Myeloid Leukaemia; DLBCL: Diffuse Large B-cell Lymphoma; MM: Multiple Myeloma

Table 1: PASD1 expression in human cells (A) cell lines and (B) tissues.